GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

Completed

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.

Key facts

Study ID

NCT01950637

Run by

Novo Nordisk A/S

People needed

4000

Starts

2012-01-01

Expected to finish

2013-01-01

Last updated by the study team

2017-01-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PATIENTS WITH T2DM:
• Diagnosed with type 2 diabetes by a healthcare professional
• Currently being treated with insulin medication, excluding premix insulin treatment
• Age at least 40 years
• Diagnosed as having type 2 diabetes over the age of 40
• HCPs:
• Primary care physician, diabetes specialist (diabetologist/endocrinologist) or diabetes specialist nurse/diabetes nurse educator
• Have a minimum of 2 years experience within current speciality
• See a minimum of 20 type 2 diabetes patients per month (40 for diabetes specialists), of which at least 10 per month must be on modern (analogue) inulins

Where it is running

• Novo Nordisk Investigational Site — Princeton, New Jersey, United States
• Novo Nordisk Investigational Site — Mississauga, Canada
• Novo Nordisk Investigational Site — Copenhagen S, Denmark
• Novo Nordisk Investigational Site — Mainz, Germany
• Novo Nordisk Investigational Site — Tokyo, Japan
• Novo Nordisk Investigational Site — Crawley, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.